Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Radiology Année : 2020

Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT

Fichier non déposé

Dates et versions

hal-03111135 , version 1 (15-01-2021)

Identifiants

Citer

Sébastien Mulé, Julia Chalaye, François Legou, Arthur Tenenhaus, Julien Caldéraro, et al.. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. European Radiology, 2020, 30 (10), pp.5348-5357. ⟨10.1007/s00330-020-06923-5⟩. ⟨hal-03111135⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More